Oncology Articles

First Multilingual App for Breast Exam Aims to Improve Early Cancer Detection
Pink Luminous Advocacy Project's Breast Awareness app is the first multilingual, unisex breast self-examination application.
Yara Abdou, MD, sheds light on the challenging path of becoming an oncologist.
The cost of antineoplastic therapy and essential supportive care medications have a substantial negative impact on patients with cancer and their families.
The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
 
BCMA Antibody-Drug Conjugate Belantamab Mafodotin Succeeds in Phase II Myeloma Trial
Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.
Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC
The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.
New Developments Propel Biosimilar Penetration of US Oncology Market
The biosimilars realm of oncology has been surrounded by a burst of clinical and regulatory news this week, with the read out of phase III findings and extension data, legality issues, and more.  
Case Studies Showcase Recent Advances in Nonsquamous, Squamous NSCLC
Practice-changing phase III trials including KEYNOTE-189, KEYNOTE-407, REVEL, and IMpower131, among several others, are laying the groundwork for how to treat patients with non–small cell lung cancer, specifically on an individualized basis.
Rituximab Biosimilar Shows Equivalency in CD20+ Non-Hodgkin Lymphoma
ABP 798, a rituximab (Rituxan) biosimilar, demonstrated clinical equivalency to reference rituximab in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Pyrotinib Combo Delays Progression in Heavily Pretreated HER2+ Breast Cancer
Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.
Publication Bottom Border
Border Publication
x